One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details
Portfolio Pulse from Vandana Singh
Bristol Myers Squibb (BMY) announced mixed results for two of its drugs. The Phase 3 YELLOWSTONE trial of Zeposia for Crohn’s disease did not meet its primary endpoint, while the KRYSTAL-12 study of Krazati for NSCLC met its primary and key secondary endpoints. Zai Lab (ZLAB) has exclusive rights to develop and commercialize adagrasib in Greater China.
April 01, 2024 | 1:44 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bristol Myers Squibb announced mixed trial results for Zeposia and Krazati, impacting its stock.
The failure of the Zeposia trial in Crohn’s disease may negatively impact BMY's stock in the short term, but the success of Krazati in the NSCLC study could offset this with potential for future revenue growth. The mixed results create uncertainty, leading to a neutral short-term impact.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Zai Lab holds exclusive rights to develop and commercialize adagrasib in Greater China, following BMY's acquisition of Mirati Therapeutics.
Zai Lab's exclusive rights to develop and commercialize adagrasib in Greater China, coupled with the positive results from the Krazati study, could lead to increased investor confidence in ZLAB. This strategic partnership and the potential market expansion for adagrasib in China are likely to have a positive short-term impact on ZLAB's stock.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70